Brevan Howard Capital Management’s Pacific Biosciences PACB Stock Holding History

Brevan Howard Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,806	Closed	-$14.3K	–	2457
2026 Q1	$14.3K	Buy	+10,806	New	+$19.3K	﹤0.01%	2113
2025 Q4	–	Sell	-101,957	Closed	-$131K	–	2160
2025 Q3	$131K	Buy	+101,957	New	+$138K	﹤0.01%	1836
2025 Q2	–	Sell	-14,129	Closed	-$16.7K	–	1964
2025 Q1	$16.7K	Buy	+14,129	New	+$21.7K	﹤0.01%	1118
2024 Q4	–	Sell	-192,956	Closed	-$328K	–	1334
2024 Q3	$328K	Sell	192,956 -29,447	-13%	-$48.4K	﹤0.01%	815
2024 Q2	$305K	Buy	222,403 +182,434	+456%	+$368K	﹤0.01%	769
2024 Q1	$150K	Buy	+39,969	New	+$234K	﹤0.01%	845

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brevan Howard Capital Management's PACB Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Pacific Biosciences (PACB) in Q2 2026, closing a stake of 10,806 shares — an estimated $14.3K sold.

Brevan Howard Capital Management first reported a position in PACB in Q1 2024 and held it in 6 quarters. The position peaked at $328K in Q3 2024. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Brevan Howard Capital Management reported no remaining Pacific Biosciences position as of Q2 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 10,806 Pacific Biosciences shares in Q2 2026, an estimated $14.3K.
Brevan Howard Capital Management first reported a position in Pacific Biosciences in Q1 2024 and held it in 6 quarters.
Brevan Howard Capital Management's Pacific Biosciences position peaked at $328K in Q3 2024.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.